Recent developments include quarterly financial results showing increased sales but widening losses, management changes, partnership extensions, and positive clinical trial outcomes.

• Natural Alternatives reported Q2 results with increased sales but a widened net loss year-over-year [N1].
• The company extended its multi-year manufacturing agreement with The Juice Plus+ Company in mid-2025 [N5].
• An amended credit facility with Wells Fargo was announced in June 2025, extending the term to 2026 [N6].
• Q4 2025 sales rose 15% year-over-year, though the net loss widened for the fiscal year [N4].
• Positive clinical trial results for the TriBsyn™ Beta-Alanine supplement were published in early 2025 [N8].
• The company reported increased net sales in Q3 2025 but continued to incur net losses [N7].
• Zacks initiated coverage of NAII with a neutral recommendation in late 2025 [N3].
• Management changes include the CFO's resignation effective May 2026, with the President acting as interim financial officer [S2].
• Industry analysis highlights niche focus and regulatory factors shaping healthcare firms including NAII [N2].

The company has demonstrated sales growth in recent quarters and fiscal years, including a 15% year-over-year increase in Q4 sales for 2025. Positive clinical trial results for its TriBsyn™ Beta-Alanine supplement may enhance product credibility and market acceptance. Management's efforts to expand global operations through the Swiss subsidiary and maintain key partnerships could support broader market reach and revenue diversification.

Despite sales growth, the company continues to report net losses, indicating challenges in achieving profitability. Management changes, including the CFO's resignation, may introduce transitional risks. The company operates in a competitive and regulated nutritional supplement market, where risks disclosed in SEC filings could materially impact business and financial results. Liquidity ratios suggest moderate short-term financial flexibility but warrant monitoring.

The company's moat is supported by its established manufacturing partnerships, proprietary nutritional supplement formulations such as TriBsyn™ Beta-Alanine, and its international operational footprint including a Swiss subsidiary. These factors contribute to customer relationships and product development capabilities that may be challenging for new entrants to replicate quickly.

• Financial Performance Risk: The company has reported net losses in recent periods, which may affect its financial stability and ability to invest in growth.
• Management Transition Risk: The resignation of the CFO and interim financial leadership may impact operational continuity and financial reporting.
• Market and Regulatory Risk: Operating in the nutritional supplement industry involves regulatory scrutiny and market competition that could adversely affect operations.
• Customer and Partnership Concentration Risk: Dependence on key partnerships and customers, such as The Juice Plus+ Company, may pose risks if these relationships change.

• Natural Alternatives International Inc is a Delaware corporation headquartered in Carlsbad, California, USA.
• The company operates in the health and nutrition sector, focusing on manufacturing and supplying nutritional supplements and ingredients.
• It has a wholly owned Swiss subsidiary, Natural Alternatives International Europe, with the CEO also serving as Managing Director to expand worldwide revenue and customer offerings.
• The CEO's compensation structure was amended in 2026 to reflect his dual roles in the US and Swiss operations.
• The company has a multi-year manufacturing agreement with The Juice Plus+ Company, extended in 2025.
• Financial disclosures include a cash and equivalents balance of approximately $9.2 million as of March 31, 2026, and current assets of about $64 million with current liabilities around $39 million, yielding a current ratio of 1.64 and a cash ratio of 0.24.
• The company reported net losses in recent periods, including a net loss of approximately $2.38 million as of September 25, 2026, with basic and diluted EPS of -$0.41.
• Recent quarterly and annual results show increased net sales but continued net losses, with Q4 sales rising 15% year-over-year in 2025 and losses widening for fiscal year 2025.
• The company published positive clinical trial results for its TriBsyn™ Beta-Alanine supplement in early 2025.
• Management changes include the resignation of the CFO in May 2026, with the President acting as Principal Financial and Accounting Officer during the search for a replacement.
• The company has an amended credit facility with Wells Fargo extended to 2026.
• Risk factors are disclosed in the 2025 Annual Report and subsequent filings, highlighting potential impacts on business, financial condition, and stock price if risks materialize.